FDA Approves Fidanacogene Elaparvovec-dzkt as One-Time Gene Therapy for Adults With Hemophilia B
The 1-time treatment may be a better alternative for patients who don’t want to undergo frequent doses of standard of care intravenous factor IX infusions.